Although low cost playing cards may help ease the burden of substantial drug costs within the short term, they do not address the systemic troubles driving up prescription selling prices while in the U.S. Broader coverage variations could deal with the basis triggers of increasing drug charges, for instance deficiency of transparency in pricing as